LakeShore Biopharma to Hold EGM for Merger Approval on June 19

LakeShore Biopharma Co., Ltd. announced an Extraordinary General Meeting (EGM) of shareholders to be held on June 19, 2026. Shareholders will vote on the previously announced Agreement and Plan of Merger, which, if approved, will result in the company becoming a privately held entity. Consequently, its ordinary shares and warrants will be delisted from public markets, including the OTC Pink tier, and cease to be registered under the Securities Exchange Act of 1934. The board of directors, based on a special committee's recommendation, unanimously approved the merger and recommends shareholders vote "FOR" the proposal.